King Pharmaceuticals KG Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.58M+7,479% | —— | —— | —— | $34K— | ||
| $3.16M— | $3.42M— | $6.84M— | $2.42M— | $0— | ||
| $10.19M+1,112% | $10.21M+737% | $17.45M+2,220% | $5.56M+780% | $841K-32.4% | ||
| $11.74M+927% | $12.06M+969% | $10.78M+813% | $5.08M+331% | $1.14M-29.5% | ||
| -$1K— | $48K— | -$24K— | $0— | $0— | ||
| $1.34M— | $405K— | $5.49M— | $1.06M— | $0— | ||
| -$6.95M-2,200% | —— | -$4.06M-846% | $70.43M+12,975% | -$302K— | ||
| $6K-93.5% | —— | $7K— | $3K— | $92K— | ||
| -$7.43M-1,786% | —— | -$5.05M-1,078% | $69.93M+12,884% | -$394K— | ||
| -72.9%-26.1pp | —— | -29%+28.1pp | 1,258.8%+1,345pp | -46.8%— | ||
| -$0.90-543% | —— | -$4,088,000.00-853% | $70,422,000.00+12,974% | -$0.14— | ||
| -$0.06— | -$6,000.49— | $0.00— | $1,000.00— | $0.00— | ||
| -$0.96-586% | —— | -$0.65-306% | $15.05+7,625% | -$0.14— | ||
| -$0.96-586% | —— | -$0.65-306% | $15.05+7,625% | -$0.14— | ||
| 7.8M+182% | 5.7M+108% | 7.7M+182% | 4.6M+68.6% | 2.7M— | ||
| 7.8M+182% | 5.7M+108% | 7.7M+182% | 4.6M+68.6% | 2.7M— | ||
| $503K— | $2.2M— | $2.94M— | $1.33M— | $0— | ||
| $2.66M— | $1.24M— | $3.76M— | $1.1M— | $0— | ||
| $2.65M— | $1.22M— | $3.9M— | $1.1M— | $0— | ||
| $2.26M— | $4.55M— | $10.41M— | -$5.96M— | $0— | ||
| -$0.9-543% | —— | -$0.53-231% | $15.16+7,680% | -$0.14— | ||
| -$0.9-543% | —— | -$0.53-231% | $15.16+7,680% | -$0.14— | ||
| -$0.06— | -$0.2— | -$0.12— | -$0.11— | $0— | ||
| $17.14M+1,399% | —— | $21.5M+1,721% | —— | $1.14M— | ||
| -$681K— | -$1.02M— | -$748K— | -$1.19M— | $0— | ||
| $1.47M— | $1.02M— | $1.72M— | $394K— | $0— | ||
| $9K-50.0% | $299K+283% | -$2.82M-16,659% | $2.78M— | $18K— | ||
| $3.12M+287% | $3.1M+164% | $1.62M+132% | $544K-5.7% | $807K-31.6% | ||
| $2.23M— | —— | $2.85M— | —— | $0— | ||
| -$6.95M-1,665% | —— | -$4.09M-853% | $70.42M+12,974% | -$394K— | ||
| $5.56M+2,369% | -$50.55M-12,779% | $23.36M+6,052% | $8.7M+2,316% | -$245K+37.6% | ||
| -$16.74M— | -$7.04M— | -$22.16M— | -$25.09M— | $0— | ||
| -$139K-151% | $810K+321% | $619K+269% | —— | $270K+174% | ||
| $3.9M— | $4.22M— | $4.13M— | $1.52M— | $0— | ||
| $2.58M+7,479% | $3.28M+7,537% | $3.49M+6,619% | $1.53M+2,735% | $34K-46.9% | ||
| -$486K— | —— | —— | -$40M— | $0— | ||
| $53M— | $42.53M— | $16.08M— | $88.33M— | $0— | ||
| -$15.13M-1,628% | -$65.71M-30,460% | -$9.7M-1,895% | -$19.86M— | -$876K— | ||
| -$14.45M-1,550% | -$64.69M-29,988% | -$8.95M-1,742% | -$18.68M— | -$876K— | ||
| $7K— | $3K— | $17K— | $1K— | $0— | ||
| $474K— | $471K— | $114K— | $490K— | $0— | ||
| $2.65M— | $1.22M— | $3.9M— | $1.1M— | $0— | ||
| $1.23M— | $1.89M— | $924K— | $141K— | $0— | ||
| $38.12M— | $47.6M— | $7.88M— | $7.31M— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is King Pharmaceuticals's revenue?
- King Pharmaceuticals (KG) generated $43.4M in revenue over the trailing twelve months, up 1160.2% year over year.
- Is King Pharmaceuticals profitable?
- King Pharmaceuticals reported $57.0M in net income over the trailing twelve months, a 131.4% net margin.
- What is King Pharmaceuticals's earnings per share?
- King Pharmaceuticals's diluted EPS over the trailing twelve months is $13.30.
- Where does King Pharmaceuticals's income statement data come from?
- Every line is extracted from King Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
